Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02648997 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
A Phase 2 study of Meningiomas, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02648997 is a Phase 2 study of Meningiomas that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02648997, a Phase 2 study of Meningiomas, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.
Conditions Studied
Interventions
- DRUG Nivolumab - 240 mg
- DRUG Ipilimumab - 1 mg/kg
- DRUG Nivolumab - 480 mg
- DRUG Nivolumab - 3 mg/kg
- RADIATION External Beam RT
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02648997
The ClinicalTrials.gov registry entry for NCT02648997 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningiomas appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab - 240 mg is the first listed.
NCT02648997 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02648997 about?
NCT02648997 is a clinical study titled "An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma". This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and ipilimumab.
What is the current status of trial NCT02648997?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2026-06-01.
What conditions does trial NCT02648997 study?
This clinical trial studies the following conditions: Meningiomas.
What interventions are being tested in trial NCT02648997?
The interventions under investigation include: Nivolumab - 240 mg (DRUG), Ipilimumab - 1 mg/kg (DRUG), Nivolumab - 480 mg (DRUG), Nivolumab - 3 mg/kg (DRUG), External Beam RT (RADIATION).
Who is sponsoring clinical trial NCT02648997?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02648997 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.